- Home
- LEGN
as 12-17-2024 4:00pm EST
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.8B | IPO Year: | 2020 |
| Target Price: | $81.54 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $32.66 - $70.13 | Next Earning Date: | 11-12-2024 |
| Revenue: | $520,183,000 | Revenue Growth: | 122.96% |
| Revenue Growth (this year): | 120.77% | Revenue Growth (next year): | 68.54% |
Latest Legend Biotech Corporation News
LEGN Breaking Stock News: Dive into LEGN Ticker-Specific Updates for Smart Investing
TipRanks
7 days ago
Legend Biotech’s CARVYKTI® Boosts Myeloma Treatment Success
MT Newswires
8 days ago
Legend Biotech Reports Advancement of Carvykti as 'Leading' Multiple Myeloma Treatment
GlobeNewswire
8 days ago
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
Investor's Business Daily
9 days ago
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
MT Newswires
9 days ago
UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating
Insider Monkey
21 days ago
Why Is Legend Biotech Corp. (LEGN) Among the Best Up and Coming Stocks to Buy According to Analysts?
Insider Monkey
a month ago
Legend Biotech Corp. (LEGN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
Insider Monkey
a month ago
Why Is Legend Biotech Corporation (LEGN) Among the Worst Performing Biotech Stocks in 2024?
Compare LEGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LEGN Legend Biotech Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.